Darolutamide Delays
Prostate-Cancer Metastasis
Darolutamide, an oral androgen receptor, was approved on July 20, 2019, for patients with nonmetastatic, castration-resistant prostate cancer based on the ARAMIS trial. The goal of the agent is to prevent metastases from occurring, which the trial demonstrated with a metastasis-free survival rate of 40.4 months versus 18.4 months compared with placebo. The most common side effect was hypertension. Read more.

Combination Increased Metastatic Breast-Cancer Survival 
Endocrine therapy is preferred in metastatic breast cancer. However, many patients are treated with chemotherapy in the metastatic setting. This study assessed an oral-chemotherapy option, palbociclib, combined with exemestane compared with oral capecitabine. The palbociclib and exemestane combination showed promising results by increasing progression-free survival in patients with metastatic breast cancer. Read more.